Written complaint "We are told that, in SMART, no drugs not approved by FDA must be used," wrote Bernard Hirschel, leader of an AIDS trial covering Switzerland, Thailand and Australia, in an e-mail sent to colleagues earlier this month. A copy of his e-mail was given to Nature by a third party last week.
The Bush administration said earlier this year that it would not allow recipients of aid under the US President's Emergency Plan for AIDS Relief to buy generic drugs with aid money until they are approved by the FDA. But the NIH is not buying drugs for any patients in the SMART trial. Anthony Fauci, head of NIAID, says it is concerned about generic drugs only because they lack approval. "NIH funded clinical trials in the developing world must meet the same standards as clinical trials conducted in the developed world, e.g. that the drugs being used are safe and meet accepted standards," Fauci wrote in a 16 September e-mail, in response to Hirschel's concerns.
But "If a country has data that the drugs they're using appear to be comparable to the drugs in other countries, and they want to enroll in this trial, we see no reason why they have to switch to FDAapproved drugs," Fauci said. But he would not say whether any of the countries trying to get into the SMART trial would meet this standard.
Negotiations stalled
Meanwhile, the delays have kept hundreds of patients from joining SMART. Brazil, Argentina and Peru are waiting for NIAID to sign a contract confirming their participation, but that step has repeatedly been delayed, say researchers. The issue has also stalled negotiations with another important potential participant -Thailand.
The delays have implications for AIDS care around the world. SMART was expected to enroll 2,264 patients this year; but has so far enrolled only 792. The South American and Thai arms of the trial would add 733 patients to the total for this year.
"Peru, Brazil and Argentina are in a holding pattern, and Thailand isn't even there because it got held up before it got started," says Fred Gordin, an infectious diseases specialist at the Veterans Affairs Medical Center in Washington DC and head of the group that has been funded by NIAID to run the SMART trial. "We really need these countries on board,"he says. Global AIDS trial denied patients as US balks at generic drug use Brand rebuff: Thailand produces the world's cheapest anti-AIDS drugs.
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